Conventional vs. conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity

International Journal of Radiation Oncology Biology Physics

Volumn 34, Issue 3, 1996, Pages 555-564

  Pollack, Alan ^a   Zagars, Gunar K ^a   Starkschall, George ^a   Childress, Constance H ^a   Kopplin, Susan ^a   Boyer, Arthur L ^a   Rosen, Isaac I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute toxicity; Conformal radiotherapy; Dosimetry; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION ENTEROPATHY; RADIATION FIELD; RADIATION INJURY; RECTUM; SEMINAL VESICLE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030059742     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02103-5     Document Type: Article

References (33)

1. Altman, D. G. Practical statistics for medical research. London: Chapman and Hall; 1991; 179-268.
2. Diaz, A.; Roach, M., III.; Marquez, C.; Coleman, L.; Pickett, B.; Wolfe, J. S.; Carroll, P.; Narayan, P. Indications for the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 30:323-329; 1994.
3. Drzymala, R. E.; Mohan, R.; Brewster, L.; Chu, J.; Goitein, M.; Harms, W.; Urie, M. Dose-volume histograms. Int. J. Radiat. Oncol. Biol. Phys. 21:71-78; 1991.
4. Egawa, S.; Wheeler, T. M.; Greene, D. E.; Scardino, P. T. Detection of residual cancer after radiotherapy by sonographically guided needle biopsy. Urology 39:358-363; 1992.
5. Greskovich, F. J.; Zagars, G. K.; Sherman, N. E.; Johnson, D. E. Complications following external beam radiation therapy for prostate cancer: An analysis of patients treated with and without staging pelvic lymphadenectomy. J. Urol. 146:798-802; 1991.
6. Kabalin, J. N.; Hodge, K. K.; McNeal, J. E.; Freiha, F. S.; Stamey, T. A. Identification of residual cancer in the prostate following radiation therapy. Role of transrectal ultrasound guided biopsy and prostate specific antigen. J. Urol. 142:326-331; 1989.
7. Kavadi, V. S.; Zagars, G. K.; Pollack, A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 30:279-287; 1994.
8. 125 seed implantation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 15:1453-1459; 1988.
9. Leibel, S. A.; Heimann, R.; Kutcher, G. J.; Zelefsky, M. J.; Burman, C. M.; Melian, E.; Orazem, J. P.; Mohan, R.; LoSasso, T. J.; Lo, H.-C.; Wiseberg, J. A.; Chapman, D. S.; Ling, C. C.; Fuks, Z. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: Preliminary results of a phase I dose-escalation study. Int. J. Radiat. Oncol. Biol. Phys. 48:55-65; 1994.
10. Marks, L. B.; Anscher, M. S. Radiotherapy for prostate cancer: Should the seminal vesicles be considered target? Int. J. Radiat. Oncol. Biol. Phys. 24:435-440; 1992.
11. Pollack, A.; Zagars, G. K.; Kopplin, S. Radiotherapy and androgen ablation for clinically localized high risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:23-20; 1995.
12. Roach, M., III.; Pickett, B.; Rosenthal, S. A.; Verhey, L.; Phillips, T. L. Defining treatment margins for six field conformal irradiation of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 28:267-275; 1994.
13. Rosenthal, S. A.: Roach, M., III.; Goldsmith, B. J.; Doggett, E. C.; Pickett. B.; Yuo, H.-S.; Soffen, E. M.; Stern, R. L.; Ryu, J. K. Immobilization improves the reproducibility of patient positioning during six-field conformal radiation therapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 27:921-926; 1993.
14. Roy, A. V.; Bower, M. E.; Hayden, J. D. Sodium thymolphthalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostate enzyme in serum. Clin. Chem. 17:1093-1102; 1971.
15. Sandler, H. M.; Perez-Tamayo, C.; Ten Haken, R. K.; Lichter, A. S. Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformal therapy. Radiother. Oncol. 23:53-54; 1992.
16. Scardino, P. T.; Frankel, J. M.; Wheeler, T. M.; Meacham, R. B.; Hoffman, G. S.; Seale, C.; Wilbanks, J. H.; Easley, J.; Carlton, C. E., Jr. The prognostic significance of postirradiation biopsy results in patients with prostatic cancer. J. Urol. 135:510-516; 1986.
17. Schellhammer, P. F.; El-Mahdi, A. M.; Wright, G. L., Jr.; Kolm, P.; Ragle, R. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 42:13-20; 1993.
18. Schild, S. E.; Casale, H. E.; Bellefontane, L. P. Movements of the prostate due to rectal and bladder distension: Implications for radiotherapy. Med. Dosim. 18:13-15; 1993.
19. Soffen, E. M.; Hanks, G. E.; Hwang, C. C.; Chu, J. C. H. Conformal static field therapy for low volume low grade prostate cancer with rigid immobilization. Int. J. Radiat. Oncol. Biol. Phys. 20:141-146; 1991.
20. Soffen, E. M.; Hanks, G. E.; Hunt, M. A.; Epstein, B. E. Conformal static field radiation therapy treatment of early prostate cancer vs. nonconformal techniques: A reduction in acute morbidity. Int. J. Radiat. Oncol. Biol. Phys. 24:485-488; 1992.
21. Stamey, T. A.; Ferrari, M. K.; Schmid, H.-P. The value of serial prostate specific antigen determination 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J. Urol. 150:1856-1859; 1993.
22. Ten Haken, R. K.; Forman, J. D.; Heimburger, D. K.; Gerhardsson, A.; McShan, D. L.; Perez-Tamayo, C.; Schoeppel, S. L.; Lichter, A. S. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int. J. Radiat. Oncol. Biol. Phys. 20:1317-1324; 1991.
23. Vijayakumar, S.; Awan, A.; Karrison, T.; Culbert, H.; Chan, S.; Kolker, J.; Low, N.; Halpern, H.; Rubin, S.; Chen, G. T. Y.; Weichselbaum, R. R. Acute toxicity during external beam radiotherapy for localized prostate cancer: Comparison of different techniques. Int. J. Radiat. Oncol. Biol. Phys. 25:359-371; 1993.
24. Washington, M.; Vijayakumar, S.; Vaida, F.; Sen, S.; Wyman, B.; Harrison, J.; Nautiyal, J.; Halpern, H.; Sutton, H.; Chen, G. T. Comparison of three patient immobilization devices in the 3-D conformal radiation therapy (3DCRT) of prostate cancer (PC). Int. J. Radiat. Oncol. Biol. Phys. 30(Suppl. 1):174; 1994.
25. Winchester, D. P.; Cox, J. D. Standards for breast-conservation treatment. CA Cancer J. Clin. 42(3): 134-162; 1992.
26. Zagars, G. K.; Kavadi, V. S.; Pollack, A.; von Eschenbach, A. C.; Sands, M. E. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer - T, N, or M? Int. J. Radiat. Oncol. Biol. Phys. 32:21-32; 1995.
27. Zagars, G. K.; Pollack, A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72:832-842; 1993.
28. Zagars, G. K.; Pollack, A. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: An early indicator of response to treatment. Radiother. Oncol. 30:121-127; 1994.
29. Zagars, G. K.; Pollack, A.; Kavadi, V. S.; von Eschenbach, A. C. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 32:293-306; 1995.
30. Zagars, G. K.; von Eschenbach, A. C.; Johnson, D. E.; Oswald, M. J. Stage C adenocarcinoma of the prostate -Analysis of 551 patients treated with external beam radiation therapy. Cancer 60:1489-1499; 1987.
31. Zeitman, A. L.; Coen, J. J.; Shipley, W. U.; Willett, C. G.; Efird, J. T. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J. Urol. 151:640-645; 1994.
32. Zhu, Y.; Boyer, A. L. X-ray dose computations in heterogeneous media using 3-dimensional FFT convolution. Phys. Med. Biol. 35:351-368; 1990.
33. Zubrod, C. G.; Schneiderman, M.; Fei, E.; Brindley, C.; Shnider, B.; Oviedo, R.; Gorman, J.; Jones, R., Jr.; Jonsson, U.; Colsky, J.; Chalmers, T.; Ferguson, B.; Dederick, M.; Holland, J.; Selawry, O.; Regelson, W.; Lasagna, L.; Owens, A. H. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. From the Eastern Cooperative Group in Solid Tumor Chemotherapy. J. Chronic Dis. 11:7-33; 1960.